# Astrana Health, Inc.: financial statements, quarterly

ASTH · Nasdaq · CIK 1083446 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/asth.md) · [Financials](/companies/asth/financials.md) · [Filings](/companies/asth/filings.md) · [Insiders](/companies/asth/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/asth/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [348](/filings/0000950170-24-125133.md) | [353 d](/filings/0001193125-26-103128.md) | [404](/filings/0000950170-25-068198.md) | [486](/filings/0000950170-25-105242.md) | [479](/filings/0001193125-25-274359.md) | [665 d](/filings/0001193125-26-103128.md) | [620](/filings/0001193125-26-213157.md) | [655](/filings/0001193125-26-342631.md) | [956](/filings/0001193125-25-274359.md) | [951 d](/filings/0001193125-26-103128.md) | [965](/filings/0001193125-26-213157.md) | [973](/filings/0001193125-26-342631.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [39.1](/filings/0000950170-24-125133.md) | [(3.9) d](/filings/0001193125-26-103128.md) | [30.1](/filings/0000950170-25-068198.md) | [30.1](/filings/0000950170-25-105242.md) | [28.4](/filings/0001193125-25-274359.md) | [0.7 d](/filings/0001193125-26-103128.md) | [20.6](/filings/0001193125-26-213157.md) | [20.3](/filings/0001193125-26-342631.md) | [19.2](/filings/0001193125-25-274359.md) | [18.4 d](/filings/0001193125-26-103128.md) | [28.5](/filings/0001193125-26-213157.md) | [34.3](/filings/0001193125-26-342631.md) |
| Interest expense | $m | [3.8](/filings/0001628280-23-038192.md) | [5.4 d](/filings/0001628280-24-008024.md) | [7.6](/filings/0001628280-24-022272.md) | [8.6](/filings/0000950170-24-094262.md) | [8.9](/filings/0001193125-25-274359.md) | [8.1 d](/filings/0001193125-26-103128.md) | [7.3](/filings/0001193125-26-213157.md) | [7.4](/filings/0001193125-26-342631.md) | [17.7](/filings/0001193125-25-274359.md) | [17.5 d](/filings/0001193125-26-103128.md) | [16.1](/filings/0001193125-26-213157.md) | [16.0](/filings/0001193125-26-342631.md) |
| Income tax | $m | [10.0](/filings/0000950170-24-125133.md) | [1.0 d](/filings/0001193125-26-103128.md) | [7.1](/filings/0000950170-25-068198.md) | [10.0](/filings/0000950170-25-105242.md) | [7.8](/filings/0001193125-25-274359.md) | [5.9 d](/filings/0001193125-26-103128.md) | [3.4](/filings/0001193125-26-213157.md) | [6.6](/filings/0001193125-26-342631.md) | [4.6](/filings/0001193125-25-274359.md) | [0.9 d](/filings/0001193125-26-103128.md) | [6.6](/filings/0001193125-26-213157.md) | [8.8](/filings/0001193125-26-342631.md) |
| Net income | $m | [22.1](/filings/0000950170-24-125133.md) | [12.4 d](/filings/0001193125-26-103128.md) | [14.8](/filings/0000950170-25-068198.md) | [19.2](/filings/0000950170-25-105242.md) | [16.1](/filings/0001193125-25-274359.md) | [(7.0) d](/filings/0001193125-26-103128.md) | [6.7](/filings/0001193125-26-213157.md) | [9.4](/filings/0001193125-26-342631.md) | [0.4](/filings/0001193125-25-274359.md) | [6.0 d](/filings/0001193125-26-103128.md) | [14.4](/filings/0001193125-26-213157.md) | [19.7](/filings/0001193125-26-342631.md) |
| Diluted EPS | $ per share | [0.47](/filings/0000950170-24-125133.md) | not reported | [0.31](/filings/0000950170-25-068198.md) | [0.40](/filings/0000950170-25-105242.md) | [0.33](/filings/0001193125-25-274359.md) | not reported | [0.14](/filings/0001193125-26-213157.md) | [0.19](/filings/0001193125-26-342631.md) | [0.01](/filings/0001193125-25-274359.md) | not reported | [0.29](/filings/0001193125-26-213157.md) | [0.40](/filings/0001193125-26-342631.md) |
| Basic EPS | $ per share | [0.47](/filings/0000950170-24-125133.md) | not reported | [0.31](/filings/0000950170-25-068198.md) | [0.40](/filings/0000950170-25-105242.md) | [0.34](/filings/0001193125-25-274359.md) | not reported | [0.14](/filings/0001193125-26-213157.md) | [0.19](/filings/0001193125-26-342631.md) | [0.01](/filings/0001193125-25-274359.md) | not reported | [0.30](/filings/0001193125-26-213157.md) | [0.40](/filings/0001193125-26-342631.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [274](/filings/0000950170-24-125133.md) | [294](/filings/0001193125-26-103128.md) | [335](/filings/0000950170-25-068198.md) | [325](/filings/0000950170-25-105242.md) | [348](/filings/0001193125-25-274359.md) | [288](/filings/0001193125-26-103128.md) | [259](/filings/0001193125-26-213157.md) | [340](/filings/0001193125-26-342631.md) | [462](/filings/0001193125-25-274359.md) | [429](/filings/0001193125-26-342631.md) | [478](/filings/0001193125-26-213157.md) | [401](/filings/0001193125-26-342631.md) |
| Current assets | $m | [476](/filings/0001628280-23-038192.md) | [462](/filings/0000950170-25-039122.md) | [539](/filings/0001628280-24-022272.md) | [570](/filings/0000950170-24-094262.md) | [597](/filings/0000950170-24-125133.md) | [638](/filings/0001193125-26-103128.md) | [613](/filings/0000950170-25-068198.md) | [729](/filings/0000950170-25-105242.md) | [884](/filings/0001193125-25-274359.md) | [863](/filings/0001193125-26-342631.md) | [1,004](/filings/0001193125-26-213157.md) | [919](/filings/0001193125-26-342631.md) |
| Total assets | $m | [1,073](/filings/0001628280-23-038192.md) | [933](/filings/0000950170-25-039122.md) | [1,226](/filings/0001628280-24-022272.md) | [1,252](/filings/0000950170-24-094262.md) | [1,285](/filings/0000950170-24-125133.md) | [1,355](/filings/0001193125-26-103128.md) | [1,331](/filings/0000950170-25-068198.md) | [1,442](/filings/0000950170-25-105242.md) | [2,237](/filings/0001193125-25-274359.md) | [2,219](/filings/0001193125-26-342631.md) | [2,359](/filings/0001193125-26-213157.md) | [2,282](/filings/0001193125-26-342631.md) |
| Current liabilities | $m | [203](/filings/0001628280-23-038192.md) | [219](/filings/0000950170-25-039122.md) | [355](/filings/0001628280-24-022272.md) | [310](/filings/0000950170-24-094262.md) | [313](/filings/0000950170-24-125133.md) | [366](/filings/0001193125-26-103128.md) | [361](/filings/0000950170-25-068198.md) | [460](/filings/0000950170-25-105242.md) | [630](/filings/0001193125-25-274359.md) | [615](/filings/0001193125-26-342631.md) | [745](/filings/0001193125-26-213157.md) | [748](/filings/0001193125-26-342631.md) |
| Total liabilities | $m | [458](/filings/0001628280-23-038192.md) | [523](/filings/0000950170-25-039122.md) | [774](/filings/0001628280-24-022272.md) | [774](/filings/0000950170-24-094262.md) | [778](/filings/0000950170-24-125133.md) | [841](/filings/0001193125-26-103128.md) | [814](/filings/0000950170-25-068198.md) | [904](/filings/0000950170-25-105242.md) | [1,682](/filings/0001193125-25-274359.md) | [1,660](/filings/0001193125-26-342631.md) | [1,781](/filings/0001193125-26-213157.md) | [1,684](/filings/0001193125-26-342631.md) |
| Long-term debt | $m | [206](/filings/0001628280-23-038192.md) | [259](/filings/0000950170-25-039122.md) | [368](/filings/0001628280-24-022272.md) | [425](/filings/0000950170-24-094262.md) | [423](/filings/0000950170-24-125133.md) | [425](/filings/0001193125-26-103128.md) | [404](/filings/0000950170-25-068198.md) | [401](/filings/0000950170-25-105242.md) | [1,002](/filings/0001193125-25-274359.md) | [991](/filings/0001193125-26-342631.md) | [980](/filings/0001193125-26-213157.md) | [883](/filings/0001193125-26-342631.md) |
| Current portion of debt | $m | [3.0](/filings/0001628280-23-038192.md) | [19.5](/filings/0000950170-25-039122.md) | [20.8](/filings/0001628280-24-022272.md) | [17.0](/filings/0000950170-24-094262.md) | [15.0](/filings/0000950170-24-125133.md) | [9.4](/filings/0001193125-26-103128.md) | [12.5](/filings/0000950170-25-068198.md) | [12.5](/filings/0000950170-25-105242.md) | [47.9](/filings/0001193125-25-274359.md) | [47.9](/filings/0001193125-26-342631.md) | [47.9](/filings/0001193125-26-213157.md) | [53.8](/filings/0001193125-26-342631.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [594](/filings/0001628280-23-038192.md) | [614](/filings/0000950170-25-039122.md) | [653](/filings/0001628280-24-022272.md) | [679](/filings/0000950170-24-094262.md) | [705](/filings/0000950170-24-125133.md) | [713](/filings/0001193125-26-103128.md) | [745](/filings/0000950170-25-068198.md) | [765](/filings/0000950170-25-105242.md) | [776](/filings/0001193125-25-274359.md) | [779](/filings/0001193125-26-342631.md) | [800](/filings/0001193125-26-213157.md) | [830](/filings/0001193125-26-342631.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [15.4 d](/filings/0000950170-24-125133.md) | [19.3 d](/filings/0001193125-26-103128.md) | [6.0](/filings/0000950170-25-068198.md) | [23.2 d](/filings/0000950170-25-105242.md) | [34.0 d](/filings/0001193125-25-274359.md) | [(10.9) d](/filings/0001193125-26-103128.md) | [16.6](/filings/0001193125-26-213157.md) | [90.9 d](/filings/0001193125-26-342631.md) | [10.0 d](/filings/0001193125-25-274359.md) | [(2.9) d](/filings/0001193125-26-103128.md) | [68.1](/filings/0001193125-26-213157.md) | [32.7 d](/filings/0001193125-26-342631.md) |
| Capital expenditure | $m | [4.1 d](/filings/0000950170-24-125133.md) | [7.1 d](/filings/0001193125-26-103128.md) | [0.4](/filings/0000950170-25-068198.md) | [2.8 d](/filings/0000950170-25-105242.md) | [2.3 d](/filings/0001193125-25-274359.md) | [2.5 d](/filings/0001193125-26-103128.md) | [3.1](/filings/0001193125-26-213157.md) | [1.4 d](/filings/0001193125-26-342631.md) | [2.6 d](/filings/0001193125-25-274359.md) | [3.1 d](/filings/0001193125-26-103128.md) | [4.0](/filings/0001193125-26-213157.md) | [3.9 d](/filings/0001193125-26-342631.md) |
| Dividends paid | $m | [1.4 d](/filings/0000950170-24-125133.md) | [59.8 d](/filings/0001193125-26-103128.md) | [0.1](/filings/0000950170-25-068198.md) | [1.8 d](/filings/0000950170-25-105242.md) | [0.2 d](/filings/0001193125-25-274359.md) | [1.9 d](/filings/0001193125-26-103128.md) | [5.5](/filings/0001193125-26-213157.md) | [0.8 d](/filings/0001193125-26-342631.md) | [0.1 d](/filings/0001193125-25-274359.md) | [1.6 d](/filings/0001193125-26-103128.md) | [0.1](/filings/0001193125-26-213157.md) | [0.1 d](/filings/0001193125-26-342631.md) |
| Share repurchases | $m | [0.2 d](/filings/0001628280-23-038192.md) | [0.5 d](/filings/0001628280-24-008024.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-274359.md) | [0.9 d](/filings/0001193125-26-103128.md) | [10.6](/filings/0000950170-25-068198.md) | [0.0 d](/filings/0000950170-25-105242.md) | [0.0 d](/filings/0001193125-25-274359.md) | [15.0 d](/filings/0001193125-26-103128.md) | [2.8](/filings/0001193125-26-213157.md) | [0.0 d](/filings/0001193125-26-342631.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [46.2](/filings/0001628280-23-038192.md) | [47.0](/filings/0001628280-24-022272.md) | [46.8](/filings/0000950170-24-094262.md) | [46.9](/filings/0000950170-24-125133.md) | [47.7](/filings/0000950170-25-068198.md) | [48.0](/filings/0000950170-25-105242.md) | [48.2](/filings/0001193125-25-274359.md) | [48.9](/filings/0001193125-26-213157.md) | [49.5](/filings/0001193125-26-342631.md) | [49.5](/filings/0001193125-25-274359.md) | [49.1](/filings/0001193125-26-213157.md) | [49.8](/filings/0001193125-26-342631.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 55,737,168 at 2026-08-03, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-342631.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.